Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;260(1):271-280.
doi: 10.1007/s00417-021-05357-z. Epub 2021 Aug 9.

Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database

Ai Kido  1   2 , Masahiro Miyake  1 , Tadamichi Akagi  1 , Hanako Ohashi Ikeda  1 , Takanori Kameda  1 , Kenji Suda  1 , Tomoko Hasegawa  1 , Shusuke Hiragi  3 , Satomi Yoshida  2 , Akitaka Tsujikawa  1 , Hiroshi Tamura  1 , Koji Kawakami  4
Affiliations

Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database

Ai Kido et al. Graefes Arch Clin Exp Ophthalmol. 2022 Jan.

Abstract

Purpose: To investigate the association between the use of topical β-blockers and subsequent asthma attacks in glaucoma patients with asthma.

Methods: This was a retrospective longitudinal cohort study using an administrative claims database. All patients aged 20 years or older who were registered in the health insurance claims database updated and managed by JMDC Inc. (Tokyo, Japan). Patients who were newly prescribed eye drops for glaucoma treatment were identified between 2011 and 2017. The patients with glaucoma were divided into two groups: β-blocker users and non-β-blocker users, based on the presence of a β-blocker in the prescribed eye drops. We investigated whether the incidence of asthma attacks in patients with previously treated asthma differed between the two groups.

Results: We categorized 17,666 patients in the β-blocker-user group and 12,609 patients in the non-β-blocker-user group. A total of 580 patients in the β-blocker group (3.28%) and 847 in the non-β-blocker group (6.72%) underwent asthma treatment before the prescription of anti-glaucoma eye drops (P < 0.001). Furthermore, 94 patients in the β-blocker-user group (0.53%) and 278 in the non-β-blocker user group (2.20%) were undergoing current treatment for asthma (P < 0.001). The adjusted hazard ratios of asthma attacks were 0.73 (95% confidence interval, 0.46-1.16, P = 0.18) in patients with a history of asthma treatment and 1.22 (95% confidence interval, 0.56-2.70, P = 0.62) in patients with current asthma treatment, compared to the non-β-blocker-user group.

Conclusion: Our results clarified that several patients with asthma were prescribed topical β-blockers for glaucoma treatment. However, asthma attacks may not be significantly attributed to topical β-blockers, even in glaucoma patients under current asthma treatment. The administration of topical β-blockers to asthma patients could be a treatment option in the absence of other treatment options, if adequate informed consent is obtained. Further studies are needed to draw a firm conclusion on this clinical question.

Keywords: Administrative database; Adverse event; Asthma; Claims database; Glaucoma; β-blocker.

PubMed Disclaimer

References

    1. Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, Shiraga F (2019) Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol 63:26–33. https://doi.org/10.1007/s10384-018-0623-4 - DOI - PubMed
    1. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study (2017) Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 5:e1221–e1234 - DOI
    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090. https://doi.org/10.1016/j.ophtha.2014.05.013 - DOI - PubMed
    1. Garway-Heath DF, Lascaratos G, Bunce C, Crabb DP, Russell RA, Shah A, United Kingdom Glaucoma Treatment Study Investigators (2013) The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology 120:68–76. https://doi.org/10.1016/j.ophtha.2012.07.028 - DOI - PubMed
    1. Ismail R, Azuara-Blanco A, Ramsay CR (2014) Variation of clinical outcomes used in glaucoma randomised controlled trials: a systematic review. Br J Ophthalmol 98:464–468. https://doi.org/10.1136/bjophthalmol-2013-304323 - DOI - PubMed

Substances